CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 27 enrolled
Drug / intervention
MORAb-066drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01761240
NCT01761240Phase 1Completed
CompareCT.gov

A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of MORAb-066, a Humanized Monoclonal Antibody to Human Tissue Factor, in Patients With Advanced or Metastatic Breast, Pancreatic, Colorectal, or Non-Small Cell Lung Cancer (Adenocarcinoma) Malignancies

Morphotek·interventional·Posted Jan 4, 2013·Updated Mar 29, 2024

In Brief

A Phase 1 clinical trial evaluating MORAb-066 for Breast Cancer and 4 related conditions. Completed, enrolled 27 participants across 2 sites.

Detailed Summary

This study is a Phase I, first in human, dose-escalation study of MORAb-066, an investigational humanized immunoglobulin G (IgG) monoclonal antibody (mAb) that targets TF-expressing malignancies that include breast, pancreatic, colorectal, and non-small-cell lung cancer (NSCLC) (adenocarcinoma). This open-label study will assess the safety, tolerability, and pharmacokinetics of MORAb-066 administered weekly. This study will identify the maximum tolerated dose (MTD) when MORAb-066 is administered IV once weekly on a 28-day cycle.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer, Pancreatic Cancer, Colorectal Cancer, Carcinoma, Non-Small-Cell Lung, Adenocarcinoma
CountriesUnited States
CollaboratorsSCRI Development Innovations, LLC

Timeline

Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJan 4, 2013
Enrollment StartJun 19, 2013
Primary CompletionFeb 9, 2016
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 13.5 years ago

Interventions

MORAb-066drug

MORAb-066 infusion.